Fig. 1: Patient characteristics in comparison to the corresponding cfDNA concentrations and total CTC counts.

For each patient, the detectable CTC count and cfDNA concentration were examined, possibly affected by the therapy status, including treatment prior to study enrollment and the time span (Δt) between the last therapy (Tx) and liquid biopsy collection (LB). CT chemotherapy, IT immunotherapy, RT radiotherapy, SURG surgery, TT targeted therapy, mo months. ‡available NGS data from whole genome amplified CTCs.